Treatment patterns and outcomes for patients with newly diagnosed glioblastoma multiforme: a retrospective cohort study.

Q1 Medicine CNS Oncology Pub Date : 2021-09-01 Epub Date: 2021-08-11 DOI:10.2217/cns-2021-0007

Srinivas Annavarapu, Anagha Gogate, Trang Pham, Kalatu Davies, Prianka Singh, Nicholas Robert

{"title":"Treatment patterns and outcomes for patients with newly diagnosed glioblastoma multiforme: a retrospective cohort study.","authors":"Srinivas Annavarapu, Anagha Gogate, Trang Pham, Kalatu Davies, Prianka Singh, Nicholas Robert","doi":"10.2217/cns-2021-0007","DOIUrl":null,"url":null,"abstract":"Aim: Investigate real-world outcomes and healthcare utilization of patients with glioblastoma multiforme (GBM) related to O6-methylguanine DNA methyltransferase (MGMT) promoter testing and methylation. Patients & methods: US Oncology Network data were analyzed for patients receiving first-line (1L) treatment for GBM. Results: Most patients received 1L radiation with temozolomide. Unadjusted median overall survival (OS) was higher in tested versus untested (median:18.1 vs 11.8 months) and in methylated versus unmethylated (median: 25.5 vs 12.4 months). Untested status, unmethylated MGMT and older age were associated with reduced OS and longer 1L treatment with increased OS. Similar findings were observed for progression-free survival. Utilization was similar between cohorts. Conclusion: In community oncology practices, MGMT methylation and testing were predictive of better survival in GBM.","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":"10 3","pages":"CNS76"},"PeriodicalIF":0.0000,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/df/e0/cns-10-76.PMC8461754.pdf","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/cns-2021-0007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/8/11 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 3

Abstract

Aim: Investigate real-world outcomes and healthcare utilization of patients with glioblastoma multiforme (GBM) related to O⁶-methylguanine DNA methyltransferase (MGMT) promoter testing and methylation. Patients & methods: US Oncology Network data were analyzed for patients receiving first-line (1L) treatment for GBM. Results: Most patients received 1L radiation with temozolomide. Unadjusted median overall survival (OS) was higher in tested versus untested (median:18.1 vs 11.8 months) and in methylated versus unmethylated (median: 25.5 vs 12.4 months). Untested status, unmethylated MGMT and older age were associated with reduced OS and longer 1L treatment with increased OS. Similar findings were observed for progression-free survival. Utilization was similar between cohorts. Conclusion: In community oncology practices, MGMT methylation and testing were predictive of better survival in GBM.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

新诊断的多形性胶质母细胞瘤患者的治疗模式和结果:一项回顾性队列研究。

目的:探讨与o6 -甲基鸟嘌呤DNA甲基转移酶(MGMT)启动子检测和甲基化相关的多形性胶质母细胞瘤(GBM)患者的现实结局和医疗保健利用情况。患者和方法:我们分析了美国肿瘤网络中接受一线(1L)治疗的GBM患者的数据。结果:大多数患者接受替莫唑胺1L放射治疗。未调整的中位总生存期(OS)在检测组高于未检测组(中位数:18.1个月vs 11.8个月)，甲基化组高于未甲基化组(中位数:25.5个月vs 12.4个月)。未测试状态、未甲基化MGMT和年龄较大与OS降低有关，而1L治疗时间较长则与OS增加有关。无进展生存期也观察到类似的结果。各队列之间的使用率相似。结论:在社区肿瘤学实践中，MGMT甲基化和检测可预测GBM患者更好的生存。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊